The immune response to acute cerebral ischemia is a major contributor to stroke
pathobiology. The inflammatory response is characterized by the participation of brain …

PF-1355 is an oral myeloperoxidase (MPO) inhibitor that successfully decreased elevated
MPO activity in mouse myocardial infarction models. Short duration PF-1355 treatment for 7 …

Excessive and prolonged activity of inflammatory monocytes is a hallmark of many diseases
with an inflammatory component. In such conditions, precise targeting of these cells could …

Monocytes (Mo) and macrophages (MΦ) are emerging therapeutic targets in malignant,
cardiovascular, and autoimmune disorders. Targeting of Mo/MΦ and their effector functions …

Background Enzymatic activity measurements of the highly oxidative enzyme
myeloperoxidase (MPO), which is implicated in many diseases, are widely used in the …

Inflammatory monocyte-derived effector cells play an important role in the pathogenesis of
numerous inflammatory diseases. However, no treatment option exists that is capable of …

Background—Exaggerated and prolonged inflammation after myocardial infarction (MI)
accelerates left ventricular remodeling. Inflammatory pathways may present a therapeutic …

Rationale: Monocytes recruited to ischemic myocardium originate from a reservoir in the
spleen, and the release from their splenic niche relies on angiotensin (Ang) II signaling …

Tissue macrophage numbers vary during health versus disease. Abundant inflammatory
macrophages destruct tissues, leading to atherosclerosis, myocardial infarction and heart …

Reactive oxygen and nitrogen species function in host defense via mechanisms that remain
controversial. Pathogens might encounter varying levels of these species, but bulk …